Orexigen Therapeutics Ireland Limited
Orexigen Therapeutics Ireland Limited is the European marketing authorisation holder for Mysimba (naltrexone/bupropion prolonged-release tablets), licensed in the UK for chronic weight management in obese or overweight adults with weight-related comorbidities. Mysimba is distributed in the UK through Consilient Health Ltd. The company is a subsidiary of the Currax Pharmaceuticals group.
How to Contact Orexigen Therapeutics Ireland Limited
Phone
Fax
020 3905 2657
0800 051 6402Medical Disclaimer
NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current. However, the knowledge and experience of a qualified healthcare professional should always be sought after instead of using the information on this page. Before taking any drug, you should always speak to your doctor or another qualified healthcare provider.
The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects. The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.
Experienced a Side Effect?
Report to Yellow Card (UK) or MedWatch (US)
